ADC Therapeutics SA ADCT 深 沪
已收盘 10-31 16:00:00 美东时间
4.46
-0.170
-3.67%
华盛通- 最 高4.67
- 今 开4.61
- 成交量 53.38万股
- 最 低 4.35
- 昨 收 4.63
- 总市值 5.00亿
- 52周最高 4.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.05
- 委 比 -20.00%
- 总股本 1.12亿
- 历史最高 56.59
- 量 比 0.82
- 振 幅 6.91%
- 历史最低 0.3599
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland, Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
10-27 19:15
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $8 to $7.
10-16 19:24
ADC Therapeutics rises on $60M PIPE financing
ADC Therapeutics (NYSE:ADCT) has entered into securities purchase agreements with certain institutional investors for a $60.0 million private investment in public equity (PIPE) financing. Under the PI...
10-13 19:50
ADC Therapeutics Announces $60 Million Private Placement
LAUSANNE, Switzerland, Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
10-13 19:30
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
10-02 04:05
ADC Therapeutics Updates Strategic Focus on ZYNLONTA
ADC Therapeutics ( ($ADCT) ) just unveiled an announcement. On September 30, 20...
09-30 21:50
国金证券：首予中国生物制药“买入”评级 目标价11.25港元
国金证券发布研报称，首次覆盖中国生物制药（01177），给予“买入”评级，预测公司2025/2026/2027年实现营业收入334.12/371.66/417...
09-23 14:43
山西证券-百利天恒-688506-EGFR×HER3 ADC有望成为肿瘤基石药物，HER2 ADC展现BIC潜力-250922
（来源：研报虎） 公司点评 百利天恒是布局ADC及多抗的创新药企业。公司核心管线EGFR×HER3双抗ADC iza-bren是潜在的泛肿瘤治疗基石药物，正在...
09-22 15:38
Aduro Clean Technologies to Participate in September Technical Conferences Across Europe and North America
LONDON, Ontario, Sept. 10, 2025 (GLOBE NEWSWIRE) – Aduro Clean Technologies Inc. ("Aduro" or the "Company") announced its participation in three key technical and industry-focused conferences in September 2025. These events provide Aduro with opportunities to showcase its Hydrochemolytic™ Technology, engage with global stakeholders, and build visibility as part of its strategy to advance sustainable innovation and the transition to a circular eco...
09-10 11:00
